Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : BLUE save search
Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry
Published: 2023-07-11 (Crawled : 21:00) - prnewswire.com
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 1.57%
H: 19.67%
C: 9.97%
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 2.2%
H: 0.27%
C: -1.62%
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 0.0%
H: 2.94%
C: -0.59%
pharma disease companies pipeline cell trial market
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Published: 2020-12-04 (Crawled : 16:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: -0.28%
H: 2.43%
C: 0.15%
collaboration disease stem cell trial phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.